The Relationship between Prothrombin Time and Bleeding in the Clinical Use of Dicumarol after Operation

By C. Adrian M. Hogben, M.D., and Edgar V. Allen, M.D.

Experienced clinicians have known for some time that bleeding owing to the use of dicumarol is not entirely a measure of the degree of prothrombin deficiency. This presentation emphasizes that bleeding may occur when prothrombin deficiency is not great and that bleeding may fail to occur when prothrombin deficiency is marked. Nonetheless great prothrombin deficiency causes bleeding more frequently than lesser degrees of prothrombin deficiency. Time is an important factor, for patients are much more apt to bleed when prothrombin deficiency has endured for several days than when it has been present only a day or so.

Since the isolation and synthesis of dicumarol by Link and his co-workers, its therapeutic value has been established. Bleeding is the only untoward effect of treatment with dicumarol. This report is an analysis of the relationship between prothrombin time and bleeding met in the clinical use of dicumarol.

The low incidence of bleeding (about 5 per cent of postoperative cases) which accompanies careful use of dicumarol has been associated with vigilant regulation of the dose of dicumarol dependent on daily determinations of prothrombin time. The method of determination of prothrombin times used at the Mayo Clinic is Magath's modification of Quick's procedure. With this test, the respective values for 100, 30, 20 and 10 per cent of normal prothrombin activity are 17 to 19 seconds, 27 seconds, 35 seconds and 60 seconds. The therapeutic goal has been to reduce the prothrombin time to between 10 and 30 per cent of normal.

In our study, bleeding was considered to result from dicumarol in all cases. In some instances it would have occurred, obviously, had dicumarol not been used, as postoperative bleeding occurs occasionally when dicumarol has not been administered. It appears improbable to us, however, that the results of this study have been significantly influenced because we have considered all bleeding to result from dicumarol. We considered hemorrhage to have been minor (epistaxis, hematuria, ecchy-

From the Division of Medicine, Mayo Clinic, Rochester, Minn.
The overlapping of prothrombin times of the two groups, controls and bleeders, is so great (fig. 2) that prothrombin time should not be used to predict the onset of bleeding or immunity from bleeding in the individual patient. Of all patients who had hemorrhages only 57 per cent had a prothrombin time greater than thirty-five seconds which was the desired value and one not generally considered to predispose to bleeding.

The mean prothrombin time of those who had major bleeding was higher than the mean prothrombin time of those who exhibited minor bleeding, but the same marked variations existed between bleeders, as a group, and controls (table 1).

<table>
<thead>
<tr>
<th></th>
<th>Number of Cases</th>
<th>Prothrombin time in seconds</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control*</td>
<td>Hemorrhage</td>
</tr>
<tr>
<td>Day of treatment</td>
<td></td>
<td>Minor</td>
</tr>
<tr>
<td>2</td>
<td>57</td>
<td>4</td>
</tr>
<tr>
<td>3</td>
<td>99</td>
<td>7</td>
</tr>
<tr>
<td>4</td>
<td>96</td>
<td>6</td>
</tr>
<tr>
<td>5</td>
<td>87</td>
<td>12</td>
</tr>
<tr>
<td>6</td>
<td>88</td>
<td>13</td>
</tr>
<tr>
<td>7</td>
<td>67</td>
<td>12</td>
</tr>
<tr>
<td>8</td>
<td>70</td>
<td>19</td>
</tr>
<tr>
<td>9</td>
<td>58</td>
<td>15</td>
</tr>
<tr>
<td>10</td>
<td>43</td>
<td>6</td>
</tr>
</tbody>
</table>

* Represents 5 per cent of the total cases without bleeding.
† Represents values, above and below which there were an equal number of cases.
relative incidence of bleeding still declined rapidly after the eighth day (fig. 3).

Thus the increased incidence of bleeding about the eighth day cannot be explained simply as the result of delayed appearance of a prolonged prothrombin time and a later decline in numbers of patients receiving dicumarol. The unique incidence remains unexplained. There is an implied dissociation between daily mean prothrombin time (single-stage method) and incidence of bleeding.

The day of most frequent bleeding was not only the eighth day of treatment but also was the tenth day after operation. This was to be expected because administration of dicumarol was started on the third day after operation in 107 of the 147 cases in which bleeding occurred. Bruzelius,3 who began treatment on the first day after operation, observed a maximal incidence of bleeding on the eighth postoperative day. This suggests that the incidence of bleeding is related more to the duration of treatment with dicumarol than to the lapse of time after operation.

**COMMENT**

The foregoing factual study leads to an important question that can be answered only in part: as longer prothrombin times may not be accompanied by an increase of bleeding sufficient to prohibit use of dicumarol, are we justified in demanding repeated prothrombin determinations as an obligatory prerequisite to dicumarol therapy? A more universal clinical use of dicumarol, sought to combat the ubiquitous threat of intravascular thrombosis, will remain unrealized when use depends on availability of repeated reliable prothrombin determinations. In spite of this pressing consideration, two aspects of therapy suggest continued dependence on prothrombin determinations.

**Fig. 2.** The percentage incidences of various prothrombin times, given separately for the two groups. For the controls, percentage incidence of all prothrombin times for the period under consideration is shown; for the bleeders, percentage incidence of stated prothrombin times of the day of bleeding. (Note: Only values obtained on fourth to twelfth days of treatment were included in calculating the incidence in each group.)

**Fig. 3.** Daily incidence of bleeding as a proportion of patients still receiving dicumarol therapy.

The prothrombin time in response to a given dose of dicumarol is unpredictable. Use of dicumarol without prothrombin determinations exposes a patient to the hazard of bleeding without guaranteeing the present high protection against intravascular thrombosis. There is also an unverified possibility that large doses of dicumarol may, by virtue of the magnitude of the dose itself, increase the risk of bleeding, a risk not necessarily reflected by a proportionate increase of prothrombin time.6 Therefore, until statistical technics have apportioned the risks, we must continue to advocate that dicumarol be used only when its administration is guided by repeated determinations of prothrombin time, in order that we can insure a deficiency of prothrombin sufficient to prevent intravascular thrombosis and in order that the therapeutic goal is achieved with the smallest possible dose of dicumarol. However, the physician must not disregard the fact that bleeding may occur when prothrombin times are not greatly prolonged. He must be espe-
cially alert for the appearance of postoperative bleeding of patients after the sixth day of treatment.

Summary

In general, patients who bled during the clinical use of dicumarol after operation had a higher prothrombin time than those who did not bleed.

Correlation between bleeding and prothrombin time was only approximate. Some patients bled when prothrombin time was not greatly prolonged and others failed to bleed when it was markedly prolonged. Although the extent of prolongation of prothrombin time was only a gross measure of the tendency toward bleeding, repeated determinations of prothrombin remain the guide to safe treatment with dicumarol.

Age apparently was not a factor in the incidence of bleeding.

There was maximal bleeding on the eighth day of treatment with dicumarol with a relatively high incidence between the sixth and tenth days.

REFERENCES

The Relationship between Prothrombin Time and Bleeding in the Clinical Use of Dicumarol after Operation

C. ADRIAN M. HOGBEN and EDGAR V. ALLEN

Circulation. 1950;2:369-372
doi: 10.1161/01.CIR.2.3.369

Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1950 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/2/3/369

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org//subscriptions/